Non-phenacetin analgesics and analgesic nephropathy: Clinical assessment of high users from a case-control study

Nephrology Dialysis Transplantation

Volumn 24, Issue 4, 2009, Pages 1253-1259

  Michielsen, Paul ^a,g   Heinemann, Lothar ^b   Mihatsch, Michael ^c   Schnülle, Peter ^d   Graf, Helmut ^e   Koch, Karl Martin ^f  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Berlin Center for Epidemiology and Health Research   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g NONE   (Belgium)

Author keywords

Analgesic nephropathy; Analgesic associated nephropathy; Combined analgesics; NSAID; Phenacetin

Indexed keywords

ACETYLSALICYLIC ACID; AMINOPHENAZONE; ANALGESIC AGENT; ANTIPYRETIC ANALGESIC AGENT; MEFENAMIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; SALICYLIC ACID;

ADULT; ANALGESIC NEPHROPATHY; ARTICLE; CAUSAL ATTRIBUTION; CLINICAL ARTICLE; DRUG USE; FEMALE; HUMAN; KIDNEY FAILURE; MALE; NEPHROLOGIST; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; RENOGRAPHY; TREATMENT DURATION;

ADULT; ANALGESICS; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHENACETIN; QUESTIONNAIRES;

EID: 65349162396     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn643     Document Type: Article

References (47)

1. Van Der Woude FJ, Heinemann LA, Graf H et al. Analgesics use and ESRD in younger age: a case-control study. BMC Nephrol 2007; 8: 15
2. Kincaid-Smith P, Nanra RS, Fairley KF. Analgesic nephropathy: a recoverable formof chronic renal failure. In: Kincaid-Smith P, Fairley KF (eds). Renal Infection and Renal Scarring. Melbourne: Mercedes Publishing Services, 1970, 385-400.
3. Elseviers MM, De Broe ME. Analgesic nephropathy in Belgium is related to the sales of particular analgesic mixtures. Nephrol Dial Transplant 1994; 9: 41-46
4. Elseviers MM, De Broe ME. Combination analgesic involvement in the pathogenesis of analgesic nephropathy: the European perspective. Am J Kidney Dis 1996; 28(suppl 1): S48-S55
5. Henrich WL,Agodoa LE, Barrett B et al.NationalKidney Foundation Position Paper. Analgesics and the kidney. AmJ Kidney Dis 1996; 27: 162-165
6. Michielsen P, De Schepper P. Analgesic nephropathy in Belgium: confusion between prevalence and incidence (Letter). Am J Kidney Dis 1996; 28: 958-959
7. Michielsen P, De Schepper P. Combination analgesic involvement in the pathogenesis of analgesic nephropathy. Am J Kidney Dis 1996; 28: 959-960; author reply 960-962
8. Delzell E, Shapiro S. Commentary on the NationalKidney Foundation Position Paper on Analgesics and the Kidney. AmJ Kidney Dis 1996; 28: 783-785
9. Delzell E, Shapiro S.Areviewof epidemiologic studies of nonnarcotic analgesics and chronic renal disease. Medicine (Baltimore) 1998; 77: 102-121
10. De Broe ME, Elseviers MM, Bengtsson U et al. Analgesic Nephropathy (Statement). Nephrol Dial Transplant 1996; 11: 2407-2408
11. Tuffs A. German nephrologists demand painkiller ban. Lancet 1996; 349: 952
12. Bach PH, Berndt WO, Delzell E et al. A safety assessment of fixed combinations of acetaminophen and acetylsalicylic acid, coformulated with caffeine. Ren Fail 1998; 20: 749-762
13. Feinstein AR, Heinemann LA, Curhan GC et al. Ad Hoc Committee of the International Study Group on Analgesics and Nephropathy. Relationship between nonphenacetin combined analgesics and nephropathy: a review. Kidney Int 2000; 58: 2259-2264
14. Heinemann LA, Garbe E, Lewis M et al. Case-control study on analgesics and nephropathy (SAN): protocol. BMC Nephrol 2005; 6: 9
15. De Broe ME, Elseviers MM. Analgesic nephropathy. N Engl J Med1998; 338: 446-452
16. Elseviers MM, De Broe ME. Analgesic nephropathy: is it caused by multi-analgesic abuse or single substance use? Drug Saf 1999; 20: 15-24
17. Murray RM. Genesis of analgesic nephropathy in the United Kingdom. Kidney Int 1978; 13: 50-57
18. Elseviers MM, De Schepper A, Corthouts R et al. High diagnostic performance of CT scan for analgesic nephropathy in patients with incipient to severe renal failure. Kidney Int 1995; 48: 1316-1323
19. Pommer W, De Broe ME. Analgesic Nephropathy. In: Davison AM et al. (eds). Oxford Textbook of Clinical Nephrology. Oxford: Oxford University Press, 2005, 1033-1048
20. Henrich WL, Clark RL, Kelly JP et al. Non-contrast-enhanced computerized tomography and analgesic-related kidney disease: report of the national analgesic nephropathy study. J Am Soc Nephrol 2006; 17: 1472-1480
21. Fored CM, Ejerblad E, Lindblad P et al. Acetaminophen, aspirin, and chronic renal failure. N Engl J Med 2001; 345: 1801-1808
22. Mihatsch MJ, Hofer HO, Gudat F et al. Capillary sclerosis of the urinary tract and analgesic nephropathy. Clin Nephrol 1983; 20: 285- 301
23. Mihatsch MJ, Khanlari B, Brunner FP. Obituary to analgesic nephropathy-an autopsy study. Nephrol Dial Transplant 2006; 21: 3139-3145
24. Gloor F. Phenacetin abuse and kidney damage. Schweiz MedWochenschr1962; 92: 61-67
25. Mihatsch MJ, Zollinger HU. The pathology of analgesic nephropathy. In: Stewart JH (ed). Analgesic and NSAID-Induced Kidney Disease. Oxford: Oxford University Press, 1993, 67-85
26. Mihatsch MJ, Brunner FP, Gloor FJG. Analgesic nephropathy and papilllary necrosis. In: Tisher CC, Brenner BM (eds). Renal Pathology. Philadelphia: J.B. Lippincott, 1999, 905-936
27. Sandler DP, Smith JC, Weinberg CR et al. Analgesic use and chronic renal disease. N Engl J Med 1989; 320: 1238-1243
28. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure with the use of acetaminophen, aspirin and nonsteroidal antiinflammatory drugs. N Engl J Med 1994; 331: 1675-1679
29. Ibanez L, Morlans M, Vidal X et al. Case-control study of regular analgesic and nonsteroidal anti-inflammatory use and end-stage renal disease. Kidney Int 2005; 67: 2393-2398
30. Barrett BJ. Acetaminophen and adverse chronic renal outcomes: an appraisal of the epidemiologic evidence. Am J Kidney Dis 1996; 28(Suppl 1): S14-S19
31. Buckalew VM. Habitual use of acetaminophen as a risk factor for chronic renal failure: a comparison with phenacetin. Am J Kidney Dis1996; 28(Suppl 1): S7-S13
32. Botting RM. Inhibitors of cyclooxygenases: mechanisms, selectivity and uses. J Physiol Pharmacol 2006; 57(Suppl 5): 113-124
33. Nasrallah R, Clark J, Hebert RL. Prostaglandins in the kidney: developments since Y2K. Clin Sci (Lond) 2007; 113: 297-311
34. Verberckmoes R, van Damme BB, Clement J et al. Bartter's syndrome with hyperplasia of renomedullary cells: successful treatment with indomethacin. Kidney Int 1976; 9: 302-307
35. Fujihara CK, Antunes GR, Mattar AL et al. Cyclooxygenase-2 (COX- 2) inhibition limits abnormal COX-2 expression and progressive injury in the remnant kidney. Kidney Int 2003; 64: 2172-2181
36. Michielsen P, Varenterghem Y. Proteinuria and nonsteroid antiinflammatory drugs. Adv Nephrol Necker Hosp 1983; 12: 139-150
37. Vriesendorp R, Donker AJ, de Zeeuw D et al. Effects of nonsteroidal anti-inflammatory drugs on proteinuria. Am J Med 1986; 81: 84-94
38. Golbetz H, Black V, Shemesh O et al. Mechanism of the antiproteinuric effect of indomethacin in nephrotic humans. Am J Physiol 1989; 256: F44-F51
39. McCarthy ET, Sharma M. Indomethacin protects permeability barrier from focal segmental glomerulosclerosis serum. Kidney Int 2002; 61: 534-541
40. Sanchez PL, Salgado LM, Ferreri NR et al. Effect of cyclooxygenase- 2 inhibition on renal function after renal ablation. Hypertension 1999; 34: 848-853
41. Wang JL, Cheng HF, Shappell S et al. A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int 2000; 57: 2334-2342
42. Cheng H, Zhang M, Moeckel GW et al. Expression of mediators of renal injury in the remnant kidney of ROP mice is attenuated by cyclooxygenase-2 inhibition. Nephron Exp Nephrol 2005; 101: e75- e85
43. Sankaran D, Bankovic-Calic N, Ogborn MR et al. Selective COX-2 inhibition markedly slows disease progression and attenuates altered prostanoid production in Han:SPRD-cy rats with inherited kidney disease. Am J Physiol Renal Physiol 2007; 293: F821-F830
44. Dey A, Maric C, Kaesemeyer WH et al. Rofecoxib decreases renal injury in obese Zucker rats. Clin Sci (Lond) 2004; 107: 561-570
45. Cheng HF,Wang CJ, Moeckel GW et al. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int 2002; 62: 929-939
46. Kitahara M, Eitner F, Ostendorf T et al. Selective cyclooxygenase- 2 inhibition impairs glomerular capillary healing in experimental glomerulonephritis. J Am Soc Nephrol 2002; 13: 1261-1270
47. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999; 106: 13S-24S